Moderna taps Samsung Biologics to fill-finish vaccines abroad

May 24, 2021

Moderna and Samsung Biologics announced an agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

The technology transfer will commence immediately at the CDMO's facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.

The deal comes as the South Korean government's vaccination campaign has been hampered by a global shortage and shipment delays. It has provided doses to just over 7 percent of its 52 million residents so far, as it aims to inoculate at least 13 million by June

Read the press release